Article

Deconstructing Stem Cell Tumorigenicity: A Roadmap to Safe Regenerative Medicine

Department of Cell Biology and Human Anatomy & Stem Cell Program, University of California Davis School of Medicine, Sacramento, CA, USA.
Stem Cells (Impact Factor: 7.7). 03/2009; 27(5):1050-6. DOI: 10.1002/stem.37
Source: PubMed

ABSTRACT Many of the earliest stem cell studies were conducted on cells isolated from tumors rather than from embryos. Of particular interest was research on embryonic carcinoma cells (EC), a type of stem cell derived from teratocarcinoma. The EC research laid the foundation for the later discovery of and subsequent work on embryonic stem cells (ESC). Both ESC isolated from the mouse (mESC) and then later from humans (hESC) shared not only pluripotency with their EC cousins, but also robust tumorigenicity as each readily form teratoma. Surprisingly, decades after the discovery of mESC, the question of what drives ESC to form tumors remains largely an open one. This gap in the field is particularly serious as stem cell tumorigenicity represents the key obstacle to the safe use of stem cell-based regenerative medicine therapies. Although some adult stem cell therapies appear to be safe, they have only a very narrow range of uses in human disease. Our understanding of the tumorigenicity of human induced pluripotent stem cells (IPSC), perhaps the most promising modality for future patient-specific regenerative medicine therapies, is rudimentary. However, IPSC are predicted to possess tumorigenic potential equal to or greater than that of ESC. Here, the links between pluripotency and tumorigenicity are explored. New methods for more accurately testing the tumorigenic potential of IPSC and of other stem cells applicable to regenerative medicine are proposed. Finally, the most promising emerging approaches for overcoming the challenges of stem cell tumorigenicity are highlighted.

2 Bookmarks
 · 
99 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The number of adults with osteoarthritis in the United States is expected to nearly double from 21.4 million in 2005 to 41.1 million by 2030. As a result, medical costs and associated comorbidity will exponentially increase in the coming decades. In the past decade, mesenchymal stem cells (MSCs) have emerged as a novel treatment for degenerative joint disease. PubMed (from 1990 to 2013) was searched to identify relevant studies. Reference lists of included studies were also reviewed. Clinical review. Level 3. We identified 9 animal and 7 human studies investigating the use of MSCs in the treatment of osteoarthritis, with varying levels of support for this therapy. While MSCs have shown potential for improving function and decreasing inflammation in animal studies, translation to patients is still in question. There is a great deal of heterogeneity in treatment methods. Standardizing the manufacturing and characterization of MSCs will allow for better comparisons.
    Sports Health A Multidisciplinary Approach 01/2015; 7(1):38-44.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Parkinson’s disease (PD) is the second most common neurodegenerative brain disorder which is around 1.5 times more common in men than in women. Currently, drug medications, surgery, and lifestyle changes are common approaches to PD, while all of them focused on reducing the symptoms. Therefore, degenerative med i-cine based on stem cell (SC) therapies has raised a promising hope. Various types of SCs have been used in basic and experimental studies relevant to PD, including embryonic pluripotential stem cells, mesenchymal (MSCs) and induced pluripotent SCs (iPSCs). MSCs have several advantages over other counterparts. They are easily accessible which can be obtained from various tissues such as bone marrow, adipose tissue, peripheral blood, etc. with avoiding ethical problems. Therefore, MSCs is attractive clinically because there are no related ethical and immunological concerns . Further studies are needed to answer some crucial questions about the different issues in SC therapy. Accordingly, SC-based therapy for PD also needed more complementary evaluation in both basic and clinical study areas.
    Medical journal of the Islamic Republic of Iran 01/2015; 29(168).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Advances of regenerative medicine in the therapy of type 1 di abetes mellitus. І. Sources of b-cell production (literature review) (part 2) M.D. Tronko, I.P. Pasteur State institution «V.P. Komisarenko Institute of Endocrinology and Metabolism, Natl Acad. Med. Sci. of Ukraine» Summary. Modern scientific data are presented in the review, on the advances of regenerative medicine in the search for sources generating insulin-producing cells for the therapy of type 1 diabetes mellitus. Keywords: type 1 diabetes mellitus, stem cells, insulin-producing cells.
    05/2012;

Preview

Download
0 Downloads
Available from